Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 66221-1-Ig - Provider product page

- Provider
- Proteintech Group
- Product name
- Alpha E-Catenin antibody
- Antibody type
- Monoclonal
- Description
- Alpha E-Catenin antibody (Cat. #66221-1-Ig) is a mouse monoclonal antibody that shows reactivity with human, mouse and has been validated for the following applications: IHC, WB,ELISA.
- Reactivity
- Human, Mouse
- Host
- Mouse
- Conjugate
- Unconjugated
- Isotype
- IgG
- Antibody clone number
- 2B7B8
- Vial size
- 20ul, 150ul
Submitted references β2-Adrenergic receptor regulates osteoblast differentiation and migration and C-terminal β-catenin phosphorylation.
Wild‑type KRAS inhibits the migration and invasion of pancreatic cancer through the Wnt/β‑catenin pathway.
Histological and Immunohistochemical Studies to Determine the Mechanism of Cleft Palate Induction after Palatal Fusion in Mice Exposed to TCDD.
YAP1 enhances cell proliferation, migration, and invasion of gastric cancer in vitro and in vivo.
Worton LE, Curtin AC, Gardiner EM
Biochemical and biophysical research communications 2025 Sep 25;781:152490
Biochemical and biophysical research communications 2025 Sep 25;781:152490
Wild‑type KRAS inhibits the migration and invasion of pancreatic cancer through the Wnt/β‑catenin pathway.
Hu X, Zhang R, Yao J, Mu B, Zhao C
Molecular medicine reports 2023 Jan;27(1)
Molecular medicine reports 2023 Jan;27(1)
Histological and Immunohistochemical Studies to Determine the Mechanism of Cleft Palate Induction after Palatal Fusion in Mice Exposed to TCDD.
Sakuma C, Imura H, Yamada T, Hirata A, Ikeda Y, Ito M, Natsume N
International journal of molecular sciences 2022 Feb 13;23(4)
International journal of molecular sciences 2022 Feb 13;23(4)
YAP1 enhances cell proliferation, migration, and invasion of gastric cancer in vitro and in vivo.
Sun D, Li X, He Y, Li W, Wang Y, Wang H, Jiang S, Xin Y
Oncotarget 2016 Dec 6;7(49):81062-81076
Oncotarget 2016 Dec 6;7(49):81062-81076
No comments: Submit comment
No validations: Submit validation data